This Monthly LabCoP ECHO session focuses on essential concepts and practical aspects critical for understanding drug resistance in tuberculosis and susceptibility testing.
The emergence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) is a major public health threat. In 2023, an estimated 400,000 individuals developed MDR-TB, yet less than half were diagnosed or identified. This diagnosis gap underscores the urgent need to scale up quality and timely drug susceptibility testing (DST) to ensure universal access to testing and initiation of appropriate treatment regimens for people with MDR/XDR-TB.
In this session, we will cover essential concepts and practical aspects critical for understanding drug resistance in tuberculosis including;
• Understanding the development of drug resistance,
• an overview of phenotypic DST methods,
• best practices for accurate and reliable DST,
• quality assurance strategies and troubleshooting &
• an introduction to the GLI DST Training package.
Presenter:
• Prof Leen Rigouts, Mycobacterial Unit of the Institute of Tropical Medicine (ITM), Antwerp, Belgium
WATCH THE FULL RECORDING
Download